Synchronous Ovarian Carcinoma with Colorectal Metastases: An Unusual Presentation

Akhtar, Kafil; Sherwani, Rana K; Anees, Afzaal

doi:10.4081/cp.2012.e53

Cited by 8 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colonoscopy, which is not part of obligatory examinations in patients with suspected OC, enables the identification of colon cancer, including synchronic cancer with OC and metastases of OC to the intestine and OC to intestine. [2,13,14] Colonoscopy enables also diagnosing non-neoplastic lesions, like bowel diverticula, and polyps.…”

Section: Introductionmentioning

confidence: 99%

Preoperative colonoscopy in patients with a supposed primary ovarian cancer

et al. 2019

View full text Add to dashboard Cite

The final diagnosis of ovarian cancer is based on surgery and pathological verification. Therefore patients who are presented to surgery may be described only as supposed ovarian cancer. According to the literature the diagnosis of ovarian cancer is confirmed only in 2/3 of them. The rest are that which mimic ovarian cancer. One of them is colorectal cancer. Colonoscopy is a gold standard in its diagnostics. On the other hand, ovarian cancer may disturb the bowel patency and makes the bowel resection or stoma necessary. The main aim was to find out the distribution of bowel patency disturbances in ovarian cancer patients during preoperative colonoscopy and to assess their predictive value with respect to the bowel resection or stoma and the additional aim to identify the pathologies which mimic the ovarian cancer. In a prospective study among 104 patients with supposed ovarian cancer, primary ovarian cancer was diagnosed in 68 patients. The rest of them suffered from colorectal cancer found at colonoscopy (N = 6), ovarian benign pathology (N = 8), ovarian borderline tumor (N = 5), and other nonandexal malignant diseases (N = 17). In ovarian cancer group dominated serous carcinoma and fedération international de gynécologie et d’obstétrique stage 3 (N = 33). During preoperative colonoscopy in ovarian cancer patients, the complete obstruction was found in 27.9%, and relative risk of bowel resection or stoma was in them 4.29 and 4.38, respectively. Another colonoscopic finding was limited patency caused by extrinsic compression (29%) which is connected with relative risk of bowel resection or stoma 3.16 and 3.21 accordingly. The last colonoscopy finding was described as moderate limited patency of unknown origin (20.6%) and the relative risk of bowel resection or stoma was 5.14 and 4.17, respectively. Colonoscopy enables the diagnoses of colorectal cancer one of the diseases which mimic ovarian cancer in patients supposed to have this diseases. Bowel patency disturbances found at colonoscopy are a potential risk factor to intestine resection or ostomy. Colonoscopy is not fully noninvasive procedure and its obligatory use in patients supposed to have ovarian cancer should be limited to the cases with specific symptoms, and tumor marker pattern. Preoperative computed tomography, dedicated to bowel examination, candidates as an alternative to colonoscopy, but not completely.

show abstract

Section: Introductionmentioning

confidence: 99%

Preoperative colonoscopy in patients with a supposed primary ovarian cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…It has also been reported in breast, lung, and melanoma cancers [ 6 , 7 ]. The presence of synchronous metastasis from an evolving ovarian cancer is even rarer [ 8 ]. Loy et al [ 9 ] reported seven cases in a series.…”

Section: Discussionmentioning

confidence: 99%

Unusual Synchronous Colonic Metastasis of Ovarian Cancer

Jaouani¹,

Zaimi²,

Jarroudi³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

Akt2/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma

Liu

Yang

2015

Tumor Biol.

View full text Add to dashboard Cite

Ovarian cancers present a mild clinical course when diagnosed early but an aggressive pathway when diagnosed in the peri- and postmenopausal periods. However, the predictability of tumor progression is stochastic and is difficult to predict. In the present study, we hypothesized to examine the key pathways that are dysregulated to promote epithelial-mesenchymal transition in serous ovarian carcinoma. Examination of these steps would help to identify ascitic fluid with cells poised for metastasis or otherwise. We focused on examining the Akt2 expression, mainly because of its report as being overamplified in the aggressive variants of ovarian cancer, as well as TGFbeta-sensitivity of Akt2 that forms the key basis for metastasis initiation of most kinds of carcinoma. We obtained primary ovarian carcinoma samples as well as ascitic fluid and distantly metastatic ovarian carcinoma to examine the expression of Akt2. The results of the study demonstrated that in malignant exfoliated ovarian cancer cells, Smad4 expression was tremendously increased in the nuclei, suggesting nuclear translocation of Smad, which thereafter may have activated ZEB2, and thereafter genomically affected the expression of E-cadherin, myosin II, and vimentin, key components for initiating and sustaining metastasis. All of these may have been stimulated by increased cellular expression of Akt2 in metastatic variants of the serous ovarian carcinoma. The reliance on Akt2 and TGF beta signaling may also potentiate the case for Akt inhibitors or small molecule inhibitors of TGFbeta signaling like doxycycline as adjunct chemotherapy in serous ovarian carcinoma, especially the metastatic variants.

show abstract

Synchronous Ovarian Carcinoma with Colorectal Metastases: An Unusual Presentation

Cited by 8 publications

References 10 publications

Preoperative colonoscopy in patients with a supposed primary ovarian cancer

Preoperative colonoscopy in patients with a supposed primary ovarian cancer

Unusual Synchronous Colonic Metastasis of Ovarian Cancer

Akt2/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma

Contact Info

Product

Resources

About